Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
38 studies found for:    "Myasthenia gravis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Mycophenolate Mofetil in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: mycophenolate mofetil
2 Recruiting Exercise for Stable Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: Exercise
3 Active, not recruiting Efficacy of Methotrexate in Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate;   Other: Placebo
4 Recruiting Phase II Trial of Rituximab In Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Rituximab;   Drug: Placebo
5 Active, not recruiting Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
6 Completed Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Intravenous ImmuneGlobulin
7 Recruiting Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Behavioral: Physical exercise programme using a rowing machine
8 Completed FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Condition: Myasthenia Gravis
Interventions: Drug: tacrolimus;   Drug: placebo
9 Active, not recruiting Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy;   Drug: prednisone
10 Active, not recruiting Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Prednisone - Azathioprine
11 Unknown  A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
12 Completed Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
Conditions: Myositis;   Myasthenia Gravis
Intervention: Drug: Rituximab
13 Completed A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Condition: Refractory Myasthenia Gravis
Intervention: Drug: Rituximab (Rituxan)
14 Completed Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Condition: Generalized Myasthenia Gravis
Interventions: Biological: GB-0998 (Intravenous immunoglobulin);   Procedure: Plasmapheresis
15 Recruiting Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Condition: Refractory Generalized Myasthenia Gravis
Interventions: Biological: Eculizumab;   Drug: Placebo
16 Enrolling by invitation ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Condition: Refractory Generalized Myasthenia Gravis
Intervention: Biological: Eculizumab
17 Recruiting Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Subcutaneous immunoglobulins
18 Not yet recruiting Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: HIZENTRA ®
19 Terminated Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Placebo;   Drug: 250 mg CK-2017357;   Drug: 500 mg CK-2017357
20 Unknown  Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Mycophenolic acid;   Drug: AZA

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years